ImmunityBio's Bladder Cancer Drug Fuels Record Quarter Amid Legal and Regulatory Scrutiny

ImmunityBio's Q1 2026 revenue jumps 168% to $44.2M, driven by bladder cancer drug ANKTIVA, despite facing FDA warnings and class-action lawsuits.

ImmunityBio’s stock surged approximately 7% on Thursday, trading between $7.46 and $7.64, following the release of preliminary first-quarter 2026 results. The biotech firm reported net product revenue of $44.2 million, a staggering 168% increase compared to the same period last year. This performance is almost entirely driven by its bladder cancer drug, ANKTIVA, whose sales volume grew by the same percentage. Sequentially, revenue rose 15% from the $38.3 million reported in the fourth quarter of 2025.

This record quarter unfolds against a backdrop of significant legal and regulatory challenges. The company is facing a series of investor class-action lawsuits related to the period from January to March 2026. Furthermore, the U.S. Food and Drug Administration (FDA) recently issued a warning concerning misleading promotional materials for ANKTIVA. ImmunityBio has submitted a formal response to the agency and promptly removed the criticized content, which included a podcast.

Financially, the company appears robust. As of March 31, 2026, it held approximately $380.9 million in cash, cash equivalents, and marketable securities. This position was bolstered by a recently completed $100 million financing round and a conversion of debt into equity by management. The gross margin for its flagship product remains exceptionally high at nearly 99%, though the company continues to report a net loss as it scales operations.

On the clinical and commercial front, progress is accelerating. ANKTIVA is now approved in five regulatory jurisdictions, making it available in roughly 34 countries. In a significant endorsement, the National Comprehensive Cancer Network (NCCN) added the drug in combination with BCG to its clinical practice guidelines in March 2026.

A key regulatory milestone is also within sight. The pivotal QUILT-2.005 study, which is fully recruited with 366 participants, has been confirmed by an independent data monitoring committee to have sufficient statistical power. Based on this, ImmunityBio plans to submit a supplemental Biologics License Application (sBLA) for the BCG-naïve indication in the fourth quarter of 2026, targeting the papillary bladder cancer market.

Analysts remain bullish on the stock's potential. Both BTIG and Piper Sandler maintain positive ratings, with price targets ranging from $12 to $13, implying substantial upside from current levels. The stock has already gained more than 250% since the start of the year.

Investors involved in the class-action litigation have until May 26, 2026, to file as lead plaintiffs. The market now awaits the final, audited first-quarter results in the upcoming 10-Q filing, which will provide the next concrete data point to assess whether ANKTIVA's commercial momentum can financially offset the ongoing legal and regulatory pressures.